SUMO4 Met55Val polymorphism is associated with coronary heart disease in Japanese type 2 diabetes individuals

Diabetes Research and Clinical Practice

Volumn 85, Issue 1, 2009, Pages 85-89

  Shimada, Takeshi ^a   Furukawa, Yasushi ^a   Furuta, Hiroto ^a   Yasuda, Kazuki ^b   Matsuno, Shohei ^a   Kusuyama, Akiko ^a   Doi, Asako ^a   Nishi, Masahiro ^a   Sasaki, Hideyuki ^a   Sanke, Tokio ^a   Nanjo, Kishio ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

Macrovascular complication; Polymorphism; SUMO4; Type 2 diabetes

Indexed keywords

METHIONINE; SUMO 4 PROTEIN; SUMO PROTEIN; UNCLASSIFIED DRUG; VALINE;

ADULT; AGED; ARTICLE; BRAIN INFARCTION; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE PREDISPOSITION; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; RISK ASSESSMENT; VASCULAR DISEASE;

AGED; AMINO ACID SUBSTITUTION; AUTOANTIBODIES; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLUTAMATE DECARBOXYLASE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; JAPAN; MALE; METHIONINE; MIDDLE AGED; REFERENCE VALUES; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS; VALINE;

EID: 67349201458     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2009.04.001     Document Type: Article

References (19)

1. Gill G. SUMO and ubiquitin in the nucleus: different functions, similar mechanisms?. Genes Dev. 18 (2004) 2046-2059
2. Hay R.T. SUMO: a history of modification. Mol. Cell 18 (2005) 1-12
3. Guo D., Li M., Zhang Y., Yang P., Eckenrode S., Hopkins D., et al. A functional variant of SUMO4, a new I kappa B alpha modifier, is associated with type 1 diabetes. Nat. Genet. 36 (2004) 837-841
4. Bohren K.M., Nadkarni V., Song J.H., Gabbay K.H., and Owerbach D. A M55V polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat shock transcription factors and is associated with susceptibility to type I diabetes mellitus. J. Biol. Chem. 279 (2004) 27233-27238
5. Tsurumaru M., Kawasaki E., Ida H., Migita K., Moriuchi A., Fukushima K., et al. Evidence for the role of small ubiquitin-like modifier 4 as a general autoimmunity locus in the Japanese population. J. Clin. Endocrinol. Metab. 91 (2006) 3138-3143
6. de Winther M.P., Kanters E., Kraal G., and Hofker M.H. Nuclear factor kappaB signaling in atherogenesis. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 904-914
7. Maedler K., Sergeev P., Ris F., Oberholzer J., Joller-Jemelka H.I., Spinas G.A., et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J. Clin. Invest. 110 (2002) 851-860
8. Cai D., Yuan M., Frantz D.F., Melendez P.A., Hansen L., Lee J., et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat. Med. 11 (2005) 183-190
9. Schmid H., Boucherot A., Yasuda Y., Henger A., Brunner B., Eichinger F., et al. Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes 55 (2006) 2993-3003
10. Zheng L., Howell S.J., Hatala D.A., Huang K., and Kern T.S. Salicylate-based anti-inflammatory drugs inhibit the early lesion of diabetic retinopathy. Diabetes 56 (2007) 337-345
11. Noso S., Fujisawa T., Kawabata Y., Asano K., Hiromine Y., Fukai A., et al. Association of small ubiquitin-like modifier 4 (SUMO4) variant, located in IDDM5 locus, with type 2 diabetes in the Japanese population. J. Clin. Endocrinol. Metab. 92 (2007) 2358-2362
12. Lin H.Y., Wang C.L., Hsiao P.J., Lu Y.C., Chen S.Y., Lin K.D., et al. SUMO4 M55V variant is associated with diabetic nephropathy in type 2 diabetes. Diabetes 56 (2007) 1177-1180
13. Wang Y., Schmeichel A.M., Iida H., Schmelzer J.D., and Low P.A. Enhanced inflammatory response via activation of NF-kappaB in acute experimental diabetic neuropathy subjected to ischemia-reperfusion injury. J. Neurol. Sci. 247 (2006) 47-52
14. Zheng L., Szabo C., and Kern T.S. Poly(ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-kappaB. Diabetes 53 (2004) 2960-2967
15. Mezzano S., Aros C., Droguett A., Burgos M.E., Ardiles L., Flores C., et al. NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol. Dial. Transplant. 19 (2004) 2505-2512
16. Marfella R.M.D.A., Di Filippo C., Siniscalchi M., Sasso F.C., Ferraraccio F., et al. The possible role of the ubiquitin proteasome system in the development of atherosclerosis in diabetes. Cardiovasc. Diabetol. 6 (2007) 35
17. Alberti K.G., and Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diab. Med. 15 (1998) 539-553
18. Rudofsky G, Jr., Schlotterer A, Nawroth PP, Bierhaus A, Hamann A. Comment on: Lin et al. (2007) SUMO4 M55V variant is associated with diabetic nephropathy in type 2 diabetes: Diabetes 56: 1177-1180. Diabetes 2007;56:e11; author reply e12-3.
19. Shin SJ, Lin HY, Wang CL, Hsiao PJ, Lin KD. Response to Comment on: Lin et al. (2007) SUMO4 M55V variant is associated with diabetic nephropathy in type 2 diabetes: Diabetes 56: 1177-1180. Diabetes 2007;56:author reply e12-3.